Gene signatures reduce the stress of preclinical drug hepatotoxicity screening.

Copple, Ian M ORCID: 0000-0003-4101-1913, Park, B Kevin ORCID: 0000-0001-8384-824X and Goldring, Christopher E (2021) Gene signatures reduce the stress of preclinical drug hepatotoxicity screening. Hepatology (Baltimore, Md.), 74 (1). pp. 513-515.

Text HEP-20-2845 REVISED CLEAN.docx - Author Accepted Manuscript Download (131kB)

Abstract

Drug-induced liver injury (DILI) is a multi-factorial process, with a diverse clinical presentation, that remains a barrier to the development of safe and effective new medicines. Improvements in preclinical screening for DILI liabilities, together with a more conservative approach to handling relatively mild cases of liver injury during clinical trials, have resulted in no drug being licenced within the past 10 years and subsequently withdrawn due to hepatotoxicity.

Item Type:	Article
Uncontrolled Keywords:	Animals, Humans, Rats, Drug Evaluation, Preclinical, Toxicity Tests, Gene Expression Regulation, Computer Simulation, Transcriptome, Datasets as Topic, Chemical and Drug Induced Liver Injury, RNA-Seq
Depositing User:	Symplectic Admin
Date Deposited:	12 Feb 2021 11:04
Last Modified:	20 Feb 2023 22:08
DOI:	10.1002/hep.31736
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3115543